Skip to main content

Canada authorizes AstraZeneca's drug for COVID prevention

Share

Canada on Thursday authorized British drugmaker AstraZeneca Plc's AZN.L antibody-based therapy for preventing COVID-19 infections, giving itself another weapon against the disease as cases rise in the country.

Health Canada has cleared the drug - Evusheld - for use in individuals aged 12 years and older who are immune compromised and unlikely to mount an adequate immune response to COVID-19 vaccination or for whom COVID-19 vaccination is not recommended.

While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.

The therapy has already been authorized in the United States and its use has also been recommended by the European Medicines Agency.

CTVNews.ca Top Stories

Opinion

Opinion I just don't get Taylor Swift

It's one thing to say you like Taylor Swift and her music, but don't blame CNN's AJ Willingham's when she says she just 'doesn't get' the global phenomenon.

Local Spotlight

DonAir force takes over at Oilers playoff games

As if a 4-0 Edmonton Oilers lead in Game 1 of their playoff series with the Los Angeles Kings wasn't good enough, what was announced at Rogers Place during the next TV timeout nearly blew the roof off the downtown arena.

Stay Connected